Results 191 to 200 of about 15,584,477 (336)

SwitchTFI: identifying transcription factors driving cell differentiation. [PDF]

Genome Biol
Martini P, Hartebrodt A, de Almeida GP, Hackstein CP, Zehn D, Blumenthal DB.   +5 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Editorial: Transcription and its regulation in bacteria

Frontiers in Microbiology, 2023
Dong Wang, Dmytro Kompaniiets, Yangbo Hu, Bin Liu   +3 more
doaj   +1 more source

Transcription Factors in Plant Gene Expression Regulation. [PDF]

Int J Mol Sci
Szymczyk P.
europepmc   +1 more source

DNA methylation modulates transcription factor occupancy chiefly at sites of high intrinsic cell-type variability [PDF]

, 2014
Matthew Maurano T, Hao Wang, Sam John, Anthony Shafer, Theresa K. Canfield, Kristen Lee, J Stamatoyannopoulos   +6 more
openalex   +1 more source

Reviewer #1 (Public Review): Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development

, 2023
Nameki Robbin A., Chang Heidi, Yu Pak, Abbasi Forough, Lin Xianzhi, Reddy Jessica, Haro Marcela, Fonseca Marcos AS, Freedman Matthew L., Drapkin Ronny, C I, Lawrenson Kate   +11 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Advantages and Possibility of Transcription Factors FOXOs in HCC. [PDF]

Cell Biochem Funct
Xiufeng G, Zhiping H, Jingzhi W.
europepmc   +1 more source

Identify key transcription factors in cell fate determination using ANANSE

, 2021
Quan Xu, Simon J. van Heeringen
openalex   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source